What information and the extent of information to be provided in an informed assent/consent form of pediatric drug trials

Bibliographic Details
Title: What information and the extent of information to be provided in an informed assent/consent form of pediatric drug trials
Authors: Nut Koonrungsesomboon, Pimlak Charoenkwan, Rungrote Natesirinilkul, Kanda Fanhchaksai, Wannachai Sakuludomkan, Nimit Morakote
Source: BMC Medical Ethics, Vol 23, Iss 1, Pp 1-10 (2022)
Publisher Information: BMC, 2022.
Publication Year: 2022
Collection: LCC:Medical philosophy. Medical ethics
Subject Terms: Informed consent, Parental consent, Assent, Consent forms, Ethics, Clinical trials, Medical philosophy. Medical ethics, R723-726
More Details: Key points Informed assent/consent remains one of the most challenging issues in pediatric drug trials, with no trustworthy clue or guidance to determine what type of information and the extent of information to be provided in an informed assent/consent form. Based on our empirical data, risk–benefit aspects related to trial participation were perceived to be more important than general information or technical details of the trial, although all the elements are deemed useful, to a certain degree, to both child participants and their parents. Both child participants and their parents did not want to read an unduly long form, with the maximum acceptable page length of no more than 5–8 pages.
Document Type: article
File Description: electronic resource
Language: English
ISSN: 1472-6939
Relation: https://doaj.org/toc/1472-6939
DOI: 10.1186/s12910-022-00856-y
Access URL: https://doaj.org/article/63bc8524e9e4420db3ff53096136bafd
Accession Number: edsdoj.63bc8524e9e4420db3ff53096136bafd
Database: Directory of Open Access Journals
More Details
ISSN:14726939
DOI:10.1186/s12910-022-00856-y
Published in:BMC Medical Ethics
Language:English